Akari Therapeutics (FRA:CLA) Institutional Ownership : 0.10% (As of Jun. 23, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Akari Therapeutics's institutional ownership is 0.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Akari Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Akari Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Akari Therapeutics Institutional Ownership Historical Data

The historical data trend for Akari Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Institutional Ownership Chart

Akari Therapeutics Historical Data

The historical data trend for Akari Therapeutics can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	0.15	0.15	0.13	0.13	0.13	0.13	0.12	0.10	0.10	0.10

Akari Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Akari Therapeutics (FRA:CLA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.